title: Comparative Effect of Atorvastatin and Rosuvastatin on 25-hydroxy-Vitamin D Levels in Non-diabetic Patients with Dyslipidaemia: A Prospective Randomized Open-label Pilot Study.
abstract: OBJECTIVE
  Low 25-hydroxy-vitamin D [25(ΟΗ)D] levels have been associated with increased risk for cardiovascular disease. Conflicting data exist regarding the effect of statins on [25(OH)D] levels. The aim of this study was to compare the effect of atorvastatin and rosuvastatin on 25(OH)D levels in non-diabetic patients with dyslipidaemia.
  
  
  METHODS
  This was a prospective randomized open-label study. Patients were assigned to atorvastatin 20 mg⁄day (n=28, age: 56.1±2.2 years, 22 females) or rosuvastatin 10 mg⁄day (n=24, age: 57.4±1.9 years, 20 females). Total cholesterol (TC), low- (LDL-C) and high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), fasting plasma glucose, insulin, glycosylated haemoglobin A1c (HbA1c) and high sensitivity C-reactive protein (hsCRP) levels were measured, and homeostatic model of assessment insulin resistance (HOMA-IR) was calculated at baseline and 12 weeks post-treatment.
  
  
  RESULTS
  There were no within or between group significant differences in 25(OH)D levels (atorvastatin: 21.7±1.9 ng/ml at baseline and 23.5±2.3 ng/ml at week 12; rosuvastatin: 25.3±1.8 and 27.0±2.4 ng/ml, respectively; p=0.172 and p=0.306 for between groups, respectively). Both statins significantly reduced TC, TG and LDL-C levels, with a greater LDL-C reduction being observed by rosuvastatin.
  
  
  CONCLUSIONS
  Atorvastatin and rosuvastatin did not significantly affect 25(OH)D levels in this study.
authors.affiliation: Department of Endocrinology, Hippokration Hospital, Thessaloniki, Greece ; Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece.
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Anagnostis
authors.affiliation: Department of Endocrinology, Hippokration Hospital, Thessaloniki, Greece.
authors.forename: Fotini
authors.initials: F
authors.lastname: Adamidou
authors.affiliation: Department of Biochemistry, Hormone Assay Laboratory, Hippokration Hospital, Thessaloniki, Greece.
authors.forename: Aristidis
authors.initials: A
authors.lastname: Slavakis
authors.affiliation: Department of Endocrinology, Hippokration Hospital, Thessaloniki, Greece.
authors.forename: Stergios A
authors.initials: SA
authors.lastname: Polyzos
authors.affiliation: Department of Endocrinology, Hippokration Hospital, Thessaloniki, Greece.
authors.forename: Despina
authors.initials: D
authors.lastname: Selalmatzidou
authors.affiliation: Department of Endocrinology, Hippokration Hospital, Thessaloniki, Greece.
authors.forename: Athanasios
authors.initials: A
authors.lastname: Panagiotou
authors.affiliation: Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece.
authors.forename: Vasilios G
authors.initials: VG
authors.lastname: Athyros
authors.affiliation: Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece.
authors.forename: Asterios
authors.initials: A
authors.lastname: Karagiannis
authors.affiliation: Department of Endocrinology, Hippokration Hospital, Thessaloniki, Greece.
authors.forename: Marina
authors.initials: M
authors.lastname: Kita
keywords: 25(OH)D; atorvastatin; glucose homeostasis; rosuvastatin; systemic inflammation; vitamin D.
references.citation: Am J Cardiol. 2003 Jul 15;92(2):152-60
references.pmid: 12860216
references.citation: Expert Opin Pharmacother. 2010 Aug;11(12):1965-70
references.pmid: 20486831
references.citation: Clin Chem Lab Med. 2010 Nov;48(11):1629-34
references.pmid: 20704534
references.citation: Cardiovasc Drugs Ther. 2009 Aug;23(4):295-9
references.pmid: 19543962
references.citation: Am J Cardiol. 2007 Apr 1;99(7):903-5
references.pmid: 17398180
references.citation: Curr Pharm Des. 2009;15(5):479-89
references.pmid: 19199976
references.citation: Lancet. 2005 Oct 8;366(9493):1267-78
references.pmid: 16214597
references.citation: Int J Endocrinol. 2010;2010:957174
references.pmid: 20016680
references.citation: Clin Chem. 2010 Nov;56(11):1696-700
references.pmid: 20817794
references.citation: Dermatoendocrinol. 2012 Jan 1;4(1):8-9
references.pmid: 22870345
references.citation: Eur Heart J. 2011 Jul;32(14):1769-818
references.pmid: 21712404
references.citation: Clin Ther. 1990 Sep-Oct;12(5):427-30
references.pmid: 2125243
references.citation: J Cardiovasc Pharmacol Ther. 2013 May;18(3):229-33
references.pmid: 23288870
references.citation: Int J Cardiol. 2012 Jan 12;154(1):78-81
references.pmid: 22019059
references.citation: Clin Ther. 1994 Sep-Oct;16(5):824-9
references.pmid: 7859242
references.citation: Curr Vasc Pharmacol. 2010 Sep;8(5):720-30
references.pmid: 20180765
references.citation: Am J Cardiol. 2011 Jun 15;107(12):1866
references.pmid: 21640222
references.citation: Diabetes Obes Metab. 2013 Aug;15(8):767-9
references.pmid: 23356580
references.citation: Am J Cardiol. 2007 Oct 15;100(8):1245-8
references.pmid: 17920365
references.citation: Int J Clin Pract. 2011 Jun;65(6):679-83
references.pmid: 21564441
references.citation: J Cardiovasc Pharmacol Ther. 2012 Dec;17(4):382-6
references.pmid: 22431864
references.citation: Open Cardiovasc Med J. 2012;6:76-80
references.pmid: 22833770
references.citation: Clin Res Cardiol. 2013 Apr;102(4):299-304
references.pmid: 23262496
references.citation: Curr Med Res Opin. 2008 Jun;24(6):1593-9
references.pmid: 18430270
references.citation: Cardiovasc Ther. 2011 Apr;29(2):146-52
references.pmid: 20370794
references.citation: Am J Cardiol. 2006 Jan 15;97(2):229-35
references.pmid: 16442368